Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Analmin - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Analmin

Approved

STANDARD

Analmin

Flamingo Pharmaceuticals Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 65c5ba25441da389
Company: Flamingo Pharmaceuticals Ltd.
Type: Standard

Approval Details

Approval Id: 65c5ba25441da389
Drug Approval Philippines Name: Analmin
Product Name: Analmin
Registration Number: DRP-285
Brand Name: Analmin
Generic Name: Mefenamic Acid
Dosage Form: Capsule
Dosage Strength: 250 mg
Manufacturer: Flamingo Pharmaceuticals Ltd.
Importer: Hexagon Pharmaceuticals
Distributor: Hexagon Pharmaceuticals
Issuance Date: 24 September 2024
Expiry Date: 10 February 2030
Pharmacologic Category: Non-Steroidal Anti-Inflammatory Durg (NSAID)
Classification: Over-the-Counter (OTC)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

65c5ba25441da389

Type

Standard

Back to Philippines FDA Approvals